When nerve pain is concentrated in one small area — the top of a foot, a knee, the groin — it can be hard to reach with traditional spinal cord stimulation. Dorsal root ganglion (DRG) stimulation targets the exact nerve junction that serves that spot. Explore how it differs from SCS, how you would test it with a trial, and what the evidence shows.
The dorsal root ganglion (DRG) is a small cluster of sensory nerve cell bodies that sits just outside the spinal cord, where the nerves from one specific region of the body gather before entering the spine. It works like a junction box for sensation. A thin lead placed next to a chosen DRG delivers gentle electrical pulses that quiet the pain signals from exactly that region — and little else.
Because each DRG serves a specific patch of the body, stimulation can be focused on an area as small as one foot or knee — without covering places that do not hurt.
Like spinal cord stimulation, DRG stimulation is tested with a temporary trial before any permanent device is placed, so you feel the relief before committing.
The DRG sits in a space with very little cushioning fluid, so the stimulation stays steady whether you are lying down, sitting, or standing — with far less of the surging that can affect SCS.
Both therapies quiet pain by interrupting nerve signals, but they aim differently. Switch between them below to see where each one places its lead, how precisely it covers a focal pain area, and how the stimulation holds up when you change position.
The pain here is focal: it lives in one foot (shown in red). Choose a therapy, then switch your body position between lying, sitting, and standing. Watch two things: how well the stimulation matches the painful spot, and whether the strength of the sensation stays steady as you move.
This is a simplified, educational illustration of how the two therapies target pain and respond to position. It is not a measurement of your own pain or a prediction of your result.
DRG stimulation grew out of spinal cord stimulation and shares its logic: a trial, then an implanted, reversible, programmable device. The differences are about where it aims and how that aim behaves.
| DRG Stimulation | Spinal Cord Stimulation (SCS) | |
|---|---|---|
| Where the lead sits | Next to a specific dorsal root ganglion, near where one nerve root exits the spine | In the epidural space over the back of the spinal cord (dorsal column) |
| Coverage | Focused on the one body region that DRG serves — foot, knee, groin | Broad bands, best for larger areas like the whole leg or lower back |
| Effect of body position | Very stable — little cushioning fluid around the DRG, so intensity changes little | More position-sensitive — sensation can surge or fade as you move |
| Best-fit pain | Focal neuropathic pain, complex regional pain syndrome (CRPS), causalgia of the lower limb | Broader neuropathic pain, persistent leg/back pain after spine surgery |
| Shared with SCS | A temporary trial before implant · reversible · programmable · no permanent change to the spine | |
DRG stimulation is FDA-approved for complex regional pain syndrome (CRPS) and causalgia of the lower limbs, and it is especially useful when pain is confined to a focal area that SCS struggles to cover. As with SCS, the trial is itself the best test of candidacy.
This is the same reassuring two-step path as spinal cord stimulation: you get to try the therapy before you commit. A short trial predicts whether a permanent implant will help.
A detailed pain history and exam to confirm the pain is focal and neuropathic, identify which DRG serves the painful area, and complete a psychological evaluation.
An outpatient procedure. One or more temporary leads are guided to the target DRG through a needle under live X-ray (fluoroscopy), with no incision.
You go home with an external stimulator and test real relief during your normal activities, paying attention to whether the focal pain quiets down.
If the trial gives meaningful relief (generally at least 50%) and better function, the permanent leads and battery (IPG) are placed as an outpatient.
The pivotal ACCURATE trial compared DRG stimulation head-to-head against SCS in 152 people with CRPS or causalgia of the lower limbs. It is the main reason DRG became an option for focal lower-limb pain.
DRG stimulation is generally low-risk, but no procedure is risk-free, and most issues relate to the hardware. Because the leads sit in a tighter, more mobile space than SCS leads, lead migration or fracture is a recognized problem and is one of the more common reasons a device needs a revision procedure. Other risks include infection, bleeding, pain at the battery pocket, and, uncommonly, a small tear in the lining around the nerves (dural puncture) causing a headache. As with any neurostimulator, some patients ultimately have the device removed (explant) if it stops helping — which is exactly what the trial is designed to reveal before a permanent implant.
DRG is a pain-management therapy, not a cure: the realistic goal is a meaningful, durable reduction in the focal pain and better daily function. Your team will also counsel you about MRI compatibility and interactions with other implanted devices. Because the trial is reversible and low-commitment, it lets you weigh real benefit against these trade-offs before deciding.
This educational resource was developed by Brown Neurosurgery to help patients and families understand dorsal root ganglion stimulation for focal nerve pain. Our neuromodulation team works alongside pain management, physiatry, and psychology to make sure DRG or SCS is offered to the right patients, and to support you through the trial, implant, and long-term programming.
Norman Prince Spine Institute — they evaluate your candidacy and place and manage the temporary trial.
Neurosurgery — they perform the permanent implant once the trial confirms meaningful relief.
For full faculty profiles, visit the Brown Neurosurgery website.